<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02708082</url>
  </required_header>
  <id_info>
    <org_study_id>COMBO-2015-1</org_study_id>
    <nct_id>NCT02708082</nct_id>
  </id_info>
  <brief_title>Glaucoma HFA / OCT Specificity Study</brief_title>
  <official_title>Glaucoma HFA / OCT Specificity Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carl Zeiss Meditec, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Carl Zeiss Meditec, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study consists of five visits over a one to three month time period.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each visit consists of optical coherence tomography (OCT) scanning (4 scans ) and two HFA&#xD;
      (Humphrey Field Analyzer) visual fields of the study eye only.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Retinal nerve fiber layer average thickness</measure>
    <time_frame>less than 3 months</time_frame>
    <description>Specificity comparison of results from the five visits will be made. Analysis of variance will be used to determine repeatability and reproducibility - results in microns.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neuroretinal rim thickness</measure>
    <time_frame>less than 3 months</time_frame>
    <description>Specificity comparison of results from the five visits will be made. Analysis of variance will be used to determine repeatability and reproducibility - results in millimeters squared.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean deviation of visual field</measure>
    <time_frame>less than 3 months</time_frame>
    <description>Specificity comparison of results from the five visits will be made. Analysis of variance will be used to determine repeatability and reproducibility - results in decibels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pattern standard deviation of the visual field</measure>
    <time_frame>less than 3 months</time_frame>
    <description>Specificity comparison of results from the five visits will be made. Analysis of variance will be used to determine repeatability and reproducibility - results in decibels.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Glaucoma</arm_group_label>
    <description>Early, moderate or advanced glaucoma, glaucoma suspects or pre-perimetric glaucoma will perform OCT scanning and HFA perimetry</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OCT scanning and HFA perimetry</intervention_name>
    <description>Imaging of the optic nerve and nerve fiber layer / measurement of visual field</description>
    <arm_group_label>Glaucoma</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult males or females 40 to 80 years old with diagnosis of glaucoma, pre-perimetric&#xD;
        glaucoma or glaucoma suspect&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult males or females 40 to 80 years old&#xD;
&#xD;
          -  Able and willing to attend the required study visits&#xD;
&#xD;
          -  Able and willing to provide consent and follow study instructions in English&#xD;
&#xD;
          -  A diagnosis by the Principal Investigator or co-investigator of glaucoma,&#xD;
             pre-perimetric glaucoma or glaucoma suspect&#xD;
&#xD;
          -  Subjects must have experience in threshold automated perimetry, having performed a&#xD;
             previous SITA (Swedish Interactive Thresholding Algorithm) threshold test within one&#xD;
             year of enrolling to the study&#xD;
&#xD;
          -  Ability to fixate that allows obtaining acceptable visual fields and OCT scans in the&#xD;
             study eye&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  â€¢ Best-corrected visual acuity less than 20/40 (study eye only) on a Snellen chart or&#xD;
             on a Snellen equivalent acuity chart&#xD;
&#xD;
               -  Spherical refraction outside -12.00 to +5.00 diopters (D) or cylinder correction&#xD;
                  outside 3.00 D (study eye only)&#xD;
&#xD;
               -  Amblyopia (either eye)&#xD;
&#xD;
               -  Narrow irido-corneal angles or a diagnosis of narrow angle glaucoma&#xD;
&#xD;
               -  Previous or current eye disease in the study eye, serious eye trauma or&#xD;
                  intraocular surgery (except cataracts with lens implants), or the presence of&#xD;
                  ocular findings that could affect the visual field, other than glaucoma&#xD;
&#xD;
               -  Cataract surgery in the study eye within six (6) months of first visit&#xD;
&#xD;
               -  Dx of any optic neuropathy other than glaucoma&#xD;
&#xD;
               -  Vitreoretinal traction or epiretinal membrane in the study eye&#xD;
&#xD;
               -  Diagnosis or history of any systemic disease / condition / treatment which is&#xD;
                  likely to affect the visual field outcome in the Study Eye other than glaucoma&#xD;
&#xD;
               -  History of diabetes, leukemia, AIDS, uncontrolled systemic high blood pressure,&#xD;
                  dementia or multiple sclerosis&#xD;
&#xD;
               -  Any disease that is likely to progress within the 3 month time period that might&#xD;
                  have visual field implications&#xD;
&#xD;
               -  A life threatening or debilitating disease&#xD;
&#xD;
               -  Participation in any study involving a non-FDA approved investigational drug&#xD;
                  (IND) within the past month, or ongoing participation in a study with a non-FDA&#xD;
                  approved or cleared investigational device (IDE)&#xD;
&#xD;
               -  Concomitant use of hydrochloroquine and/or chloroquine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Callan</last_name>
    <role>Study Director</role>
    <affiliation>Carl Zeiss Meditec, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas Callan</last_name>
    <phone>9255574834</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Carl Zeiss Meditec, Inc.</name>
      <address>
        <city>Dublin</city>
        <state>California</state>
        <zip>94568</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>T Callan</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>February 24, 2016</study_first_submitted>
  <study_first_submitted_qc>March 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2016</study_first_posted>
  <last_update_submitted>March 9, 2016</last_update_submitted>
  <last_update_submitted_qc>March 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

